Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

Cullinan will review Phase 3 REZILIENT3 interim data that met the progression-free survival primary endpoint in a dedicated virtual investor event.

Rhea-AI Summary

Cullinan Therapeutics (CGEM) will host a virtual analyst and institutional investor event on September 14, 2026, at 8:00 a.m. ET to discuss Phase 3 REZILIENT3 data for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation-positive NSCLC.

The event follows presentation of the planned interim analysis results in Presidential Symposium 2 at the IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea. The REZILIENT3 trial previously met its primary endpoint of progression-free survival at this interim analysis. The webcast will feature CEO Nadim Ahmed and Chief Medical Officer Jeffrey Jones and will be accessible live and as an archived replay via the events page of Cullinan Therapeutics’ investor relations website.

Positive

• Phase 3 REZILIENT3 met primary endpoint of progression-free survival at planned interim analysis

Negative

• None.

Key Terms

progression-free survival, nsclc, t cell engagers

3 terms

progression-free survival medical

"met its primary endpoint of progression-free survival at a planned interim analysis"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

nsclc medical

"mutation-positive non-small cell lung cancer (NSCLC)"

NSCLC stands for non-small cell lung cancer, which is the most common type of lung cancer. It develops in the lungs and can spread to other parts of the body, making it serious but often treatable if caught early. Understanding NSCLC helps people recognize the importance of lung health and early detection.

t cell engagers technical

"developing potential first- or best-in-class, disease-modifying T cell engagers"

T cell engagers are engineered molecules that act like a matchmaker or bridge, linking a patient’s T cells (immune cells that kill infected or cancerous cells) directly to diseased cells so the immune system can destroy them. For investors, they matter because successful T cell engagers can become high-value therapies with steep clinical and regulatory milestones that drive a biotech company’s revenue potential and share price, while failures or safety issues can rapidly reduce valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposium 2 on Sunday, September 13, 2026

Company to host a virtual event on Monday, September 14, 2026, at 8:00 a.m. ET

CAMBRIDGE, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event for analysts and institutional investors on Monday, September 14, 2026, at 8:00 a.m. ET to discuss the results from the planned interim analysis of the Phase 3 REZILIENT3 trial presented in Presidential Symposium 2 at the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference on Lung Cancer (WCLC), being held September 12-15, 2026 in Seoul, South Korea.

As previously announced, the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC) met its primary endpoint of progression-free survival at a planned interim analysis.

Virtual Event Details

Cullinan Therapeutics will host a virtual event for analysts and institutional investors on Monday, September 14, 2026, at 8:00 a.m. ET, following the Presidential Symposium presentation. Participants from Cullinan Therapeutics include Nadim Ahmed, Chief Executive Officer, Jeffrey Jones, MD, MBA, Chief Medical Officer.

A live webcast will be available via the events page of Cullinan Therapeutics’ investor relations website at https://investors.cullinantherapeutics.com/events. A replay will be archived on the website following the event.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.

Contacts

Cullinan Therapeutics
Investors
Nick Smith
+1 401.241.3516
Nsmith@cullinantx.com

Media
Rose Weldon
+1 215.801.7644
Rweldon@cullinantx.com

FAQ

When and how can investors access Cullinan Therapeutics’ virtual event on the REZILIENT3 data?

The virtual event for analysts and institutional investors will take place on Monday, September 14, 2026, at 8:00 a.m. ET. A live webcast will be available via the events page of Cullinan Therapeutics’ investor relations website at https://investors.cullinantherapeutics.com/events, and a replay will be archived on the same site following the event.

Who from Cullinan Therapeutics is scheduled to participate in the REZILIENT3 virtual event?

Participants from Cullinan Therapeutics are expected to include Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, MD, MBA, Chief Medical Officer.

Where and when will the REZILIENT3 interim analysis results be presented at WCLC 2026?

The results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation-positive NSCLC will be presented in Presidential Symposium 2 on Sunday, September 13, 2026, at the IASLC 2026 World Conference on Lung Cancer, held September 12–15, 2026, in Seoul, South Korea.